Skip to content
Published studies and FDA documents are linked throughout.
Doctor CJC-1295

CJC-1295 findings set down carefully. No practice runs here.

Menu

CJC-1295 sources

The papers and public documents cited in this guide, with the question each can help answer.

Using this source list

Each entry describes the source's role rather than treating a citation as an endorsement. Human pharmacology, animal development work, regulatory assessment, and sport rules answer different questions. A finding needs to stay attached to the ingredient, population, and outcome that produced it.

The human papers concern the long-acting DAC form. Their hormone measurements do not establish a treatment for the everyday benefits often claimed for CJC-1295. FDA documents provide broader safety and regulatory context, while a terminated trial record identifies a gap rather than supplying unpublished results.

Original research

Teichman and colleagues, 2006: persistence and hormone response. This healthy-adult investigation measured CJC-1295 exposure, growth hormone, IGF-1, and short-term tolerability. It is the main source for the prolonged hormone response described here. Its findings do not establish improved sleep, physical performance, or a dose for treating a condition. DOI: 10.1210/jc.2005-1536.

Ionescu and Frohman, 2006: pulses during longer stimulation. This human report examined the pattern of growth hormone secretion during exposure to long-acting CJC-1295. Pulses persisted alongside higher background concentrations. That observation concerns a hormone pattern; it does not demonstrate long-term safety or a clinical benefit.

Sackmann-Sala and colleagues, 2009: changes in blood-protein patterns. The researchers studied serum proteins in eleven healthy men after CJC-1295 exposure. The work explored markers associated with GH/IGF-1 activity. It was not a trial of how participants slept, exercised, or felt in everyday life. DOI: 10.1016/j.ghir.2009.03.001.

Jetté and colleagues, 2005: the albumin-binding development work. Rat experiments and laboratory testing helped explain why the long-acting analog could produce an extended response. This paper supports the development history and mechanism. Its species and experimental setting limit what can be inferred about effects in people. DOI: 10.1210/en.2004-1286.

The registered clinical trial

ClinicalTrials.gov, NCT00267527: the terminated abdominal-fat study. This record describes a trial involving people with HIV and excess abdominal fat. The registry marks it terminated and provides no posted results. It documents that a clinical question was investigated, but it cannot supply an effectiveness estimate or resolve the cause of the death described in anecdotal reports.

FDA assessments and compounding information

FDA, 2024: assessment of five CJC-1295-related ingredients. The advisory-committee material reviews naming, chemistry, published human data, adverse findings, and the proposed use in growth hormone deficiency. It provides the safety context used throughout this guide. An agency concern, a committee recommendation, and an approved prescribing label are different forms of evidence.

FDA, 2024: the ipamorelin ingredient review. This separate document considers ipamorelin's pharmacology, evidence, and safety concerns. It helps explain why a CJC-1295 combination cannot borrow reassurance from the CJC-1295 papers alone. Findings about one ingredient do not establish the benefit or regimen of a fixed blend.

FDA safety-risk page, content current April 22, 2026: withdrawn nominations and retained concerns. The page lists CJC-1295 among withdrawn nominations, with safety concerns retained. It gives no individual withdrawal date. Ipamorelin acetate also appears in the outsourcing-facility Category 2 table. Neither entry is an approval of the combination or permission to compound it.

FDA consumer explanation: risks of compounded medicines. This source explains that compounded preparations do not receive FDA approval and are not checked by FDA for safety, effectiveness, or quality before marketing. It supplies the distinction between a prescription decision and approval of a finished medicine, rather than a finding about one person's care.

Sport rules

World Anti-Doping Agency, 2026: the international prohibited list. Section S2 names CJC-1295 among substances prohibited at all times. The document addresses sport eligibility, including periods outside competition. It is not a clinical safety review and cannot determine whether a particular symptom or health outcome is related to a compound.

Continue reading

The research record